<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512131</url>
  </required_header>
  <id_info>
    <org_study_id>Dialysis mode_coagulation</org_study_id>
    <nct_id>NCT04512131</nct_id>
  </id_info>
  <brief_title>Impact of Dialysis Modality on Coagulation and Platelet Function</brief_title>
  <official_title>Impact of Dialysis Modality on Coagulation and Platelet Function in Critically Ill Patients: Intermittent Hemodialysis vs. Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the impact of dialysis modality (intermittent hemodialysis or&#xD;
      continuous renal replacement therapy) in coagulation and platelet function in critically ill&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An prospective observational study will be conducted to confirm the impact of two dialysis&#xD;
      modalitites on coagulation and platelet function in critically ill patients requiring renal&#xD;
      replacement therapy using laboratory test, Multiplate and ROTEM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>clotting time (CT) in EXTEM in rotational thromboelastometry (ROTEM)</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of changes in CT in EXTEM of ROTEM (seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiplate® platelet function analysis area under curve unit</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of platelet function using Multiplate®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clot formation time (CFT) in EXTEM</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of CFT in EXTEM using ROTEM (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude 10 minutes after CT (A10) in EXTEM</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of A10 in EXTEM using ROTEM (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>α-angle in EXTEM</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of α-angle in EXTEM using ROTEM (º)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal clot firmness (MCF) in EXTEM</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of MCF in EXTEM using ROTEM (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of prothrombin time (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated partial thromboplastin time</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of activated partial thromboplastin time (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein C</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of Protein C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein S</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of Protein S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>before and after applying each mode of dialysis (4 hours in intermittent hemodialysis and 48 hours in continuous renal replacement therapy</time_frame>
    <description>the difference of platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the amount of blood transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>the amount of blood transfusion for 24 hours after taking second blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic changes</measure>
    <time_frame>24 hours</time_frame>
    <description>changes of mean arterial pressure &gt; 20 %, increased vasopressor/inotropics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of characteristics or amount of drainage</measure>
    <time_frame>24 hours</time_frame>
    <description>changes of characteristics or amount of drainage</description>
  </secondary_outcome>
  <other_outcome>
    <measure>complication related to bleeding</measure>
    <time_frame>24 hours</time_frame>
    <description>gastrointestinal bleeding-hematochezia/melena, intra-abdominal bleeding, airway bleeding</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Intermittent hemodialysis</arm_group_label>
    <description>patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous renal replacement therapy</arm_group_label>
    <description>patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dialysis mode</intervention_name>
    <description>intermittent hemodialysis or continuous renal replacement therapy</description>
    <arm_group_label>Intermittent hemodialysis</arm_group_label>
    <arm_group_label>continuous renal replacement therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill adult patients in surgical intensive care unit requiring renal replacement&#xD;
        therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Critically ill adult patients in surgical intensive care unit who require renal&#xD;
        replacement therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with anti-coagulation therapy due to thrombosis/embolism&#xD;
&#xD;
          -  Patients who take anti-platelet drug due to cardiac or cerebrovascular diseased&#xD;
&#xD;
          -  Patients treated with pharmacological prophylaxis of deep vein thrombosis&#xD;
&#xD;
          -  Patients who received blood products within 24 hours of dialysis initiation&#xD;
&#xD;
          -  Patients who do not want life-sustaining care including renal replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho Geol Ryu, Ph.D.</last_name>
    <phone>82-2-2072-2469</phone>
    <email>hogeol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyunjae Im</last_name>
    <phone>+821087098801</phone>
    <email>neptunelight88@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hogeol Ryu, MD, PhD</last_name>
      <phone>+82220722469</phone>
      <phone_ext>82-2-2072-2469</phone_ext>
      <email>hogeol@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hyunjae Im</last_name>
      <phone>+821087098801</phone>
      <phone_ext>82-2-2072-1683</phone_ext>
      <email>neptunelight88@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ho Geol Ryu</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

